The estimated Net Worth of John D Diekman is at least $1.9 Millón dollars as of 4 February 2022. John Diekman owns over 1,000 units of Zai Lab stock worth over $1,458,456 and over the last 5 years he sold ZLAB stock worth over $444,940. In addition, he makes $0 as Independent Director at Zai Lab.
Sign up
John Diekman ZLAB stock SEC Form 4 insiders trading
John has made over 5 trades of the Zai Lab stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of ZLAB stock worth $50,170 on 4 February 2022.
The largest trade he's ever made was buying 250,000 units of Zai Lab stock on 28 May 2019 worth over $2,500,000. On average, John trades about 25,400 units every 98 days since 2019. As of 4 February 2022 he still owns at least 67,615 units of Zai Lab stock.
You can see the complete history of John Diekman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Diekman biography
Dr. John D. Diekman Ph.D. serves as Independent Director of the Company. Dr. Diekman is founding partner of 5AM Ventures, where he has served since 2002. He is chairman of the board of directors of IDEAYA Biosciences, Inc., an oncology target discovery company; director of Cleave Therapeutics, Inc., a cancer therapeutic company; and Wildcat Discovery Technologies, Inc., a technology company that discovers materials for energy storage applications; charter trustee of Princeton University; chairman of the board of directors of The Scripps Research Institute; and a member of the advisory board of the Schaeffer Center for Health Policy and Economics at the University of Southern California. During the last five years, Dr. Diekman also served as director of Calibrium LLC, a biopharmaceutical research company focused on diabetes and other metabolic diseases; Cellular Research, Inc., a single-cell genomics startup; and PhaseRx Inc., a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children. Dr. Diekman holds an A.B. in Organic Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University.
How old is John Diekman?
John Diekman is 77, he's been the Independent Director of Zai Lab since 2017. There are no older and 24 younger executives at Zai Lab.
What's John Diekman's mailing address?
John's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.
Insiders trading at Zai Lab
Over the last 4 years, insiders at Zai Lab have traded over $44,173,112 worth of Zai Lab stock and bought 19,000 units worth $666,380 . The most active insiders traders include Ying Du, William Lis y John D Diekman. On average, Zai Lab executives and independent directors trade stock every 14 days with the average trade being worth of $432,845. The most recent stock trade was executed by Richard Gaynor on 3 September 2024, trading 2,500 units of ZLAB stock currently worth $48,750.
What does Zai Lab do?
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
What does Zai Lab's logo look like?
Complete history of John Diekman stock trades at Zai Lab y IDEAYA Biosciences
Zai Lab executives and stock owners
Zai Lab executives and other stock owners filed with the SEC include:
-
Dr. Ying Du,
Founder, Chairperson & CEO -
Frazor Titus Edmondson III,
Chief Legal Officer & Corp. Sec. -
Tao Fu,
Chief Strategy Officer -
Ki Chul Cho,
Chief Financial Officer -
Dr. Alan Bart Sandler M.D.,
Pres & Head of Global Devel. in Oncology -
Leon Moulder,
Independent Director -
William Lis,
Independent Director -
Chen Kai-Xian,
Independent Director -
John Diekman,
Independent Director -
Peter Wirth,
Director -
Nisa Leung,
Director -
Hei Yongjiang,
Chief Medical Officer, Oncology -
Harald Reinhart,
Chief Medical Officer, Autoimmune and Infectious Diseases -
William Liang,
Chief Commercial Officer -
F. Ty Edmondson,
Chief Legal Officer -
Valeria Fantin,
Chief Scientific Officer -
Jonathan Wang,
Senior Vice President, Head of Business Development -
James Yan,
Executive Vice President, Preclinical Development and Program & Portfolio Management -
Ning Xu,
Executive Vice President, Head of Clinical and Regulatory -
Billy Cho,
Chief Financial Officer -
Fu Tao,
President, Chief Operating Officer, Director -
Du Ying,
Chairman of the Board, Chief Executive Officer, Co-Founder -
Danielle Halstrom,
Sr. VP & Global Head of Communications -
Ann E. Beasley J.D.,
Chief Compliance Officer -
Dr. Harald Reinhart M.D.,
Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases -
Dr. James Yan DABT, M.D., Ph.D.,
Chief Operating Officer of R&D -
Dr. Jonathan J. Wang M.B.A., MBA, Ph.D.,
Exec. VP & Head of Bus. Devel. -
Dr. Ning Xu M.D.,
Exec. VP & Head of Clinical Operations -
Ann Beasley,
Chief Compliance Officer -
Scott W Morrison,
-
Richard Gaynor,
-
Rafael Amado,
See Remarks -
Michel Vounatsos,
-
William Ki Chul Cho,
Chief Financial Officer -
Alan B. Sandler,
Head of Global Dev., Oncology -
Yi Liang,
CCO & President, Greater China -
Joshua L Smiley,
See Remarks -
Yajing Chen,
Chief Financial Officer